The use of diammonium glycyrrhizinate in the treatment of hepatic dysfunction in burn patients.
- Author:
Han-hong JIN
1
;
Guo-ping ZHENG
;
Wu-rong CHEN
;
Dan LIU
;
Xiang CHENG
;
Jia-biao REN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Alanine Transaminase; blood; Aspartate Aminotransferases; blood; Burns; blood; drug therapy; physiopathology; Female; Glycyrrhizic Acid; therapeutic use; Humans; Liver; physiopathology; Liver Diseases; drug therapy; Liver Function Tests; Male; Middle Aged
- From: Chinese Journal of Burns 2005;21(5):353-355
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the protective effect of diammonium glycyrrhizinate on hepatic function in burn patients.
METHODSTwenty burn patients with hepatic dysfunction were enrolled in the study and were randomly divided into 2 groups, i. e. treatment (T, n = 10, with conventional treatment and intravenous infusion of 150 mg diammonium glycyrrhizinate per day for 14 days), and control (C, n = 10, with conventional treatment) groups. The blood samples in both groups were collected before and 7 and 15 days after the treatment. The serum contents of ALT, AST, GGT, ALP and PA in the blood samples were determined and analyzed comparatively.
RESULTSThere was obvious difference in the serum contents of ALT, AST, GGT, ALP and PA in the T group before treatment (168 +/- 46 U/L, 104 +/- 29 U/L, 162 +/- 37 U/L, 149 +/- 17 U/L, 310 +/- 35 mg/L, respectively) and 15 days after treatment (51 +/- 9 U/L, 31 +/- 3 U/L, 56 +/- 10 U/L, 103 +/- 9 U/L, 372 +/- 44 mg/L, respectively, P < 0.05). There was no difference in these indices in the C group before and after treatment (P > 0.05).
CONCLUSIONDiammonium glycyrrhizinate seemed to be beneficial to the management of postburn hepatic dysfunction with obvious rapid depression of hepatic enzymes.